黑料官网

header-logo
GettyImages-609179959-hero
headshot

Deepak Kilari, MD

Associate Professor

view physician profile

Locations

  • Froedtert Hospital
  • Clinical Cancer Center - Froedtert Hospital

Specialties

  • Hematology
  • Medical Oncology

Languages

  • English, Telugu, Hindi

New & Established Patients Call

Education

  • MD - Doctor of Medicine

Biography

Deepak Kilari, MD, is an assistant professor in the division of hematology and oncology at the 黑料官网. Dr. Kilari moved back to the United States after finishing medical school at Andhra Medical College, India, to finish his internal medicine training at New York Methodist Hospital. In the course of his residency, he developed an interest in Oncology during his rotations at the Memorial Sloan Kettering Cancer Center, New York. Subsequently, he completed a fellowship in hematology and oncology at the University of Rochester, where he also served as a chief fellow. He received the American Society of Clinical Oncology (ASCO) Foundation Merit award in 2013. Dr. Kilari practices at Froedtert & the 黑料官网 Clinical Cancer Center and Moorland Reserve Clinic where he specializes in the management of patients with Genitourinary malignancies.

Research Interests

Dr. Kilari's clinical research interests focus on the development of better treatment options for patients with genitourinary malignancies. Dr. Kilari is Board Certified in Medical Oncology and Hematology.

Publications

  • (Jiang CY, Hwang H, Epstein IY, Bakaloudi DR, Talukder R, Taylor AK, Nizam A, Jindal T, Glover MJ, Khaki AR, Barata PC, Nguyen CB, Oh E, Davis NB, Mabey H, Hoimes CJ, Evans ST, Abuqayas B, Lemke E, Tsung I, Qiao W, Kilari D, Zakharia Y, Bilen MA, Milowsky MI, Shah SA, Gupta S, Emamekhoo H, Bellmunt J, Alva AS, Grivas P, Msaouel P, Koshkin VS, Campbell MT, Alhalabi O.) Oncologist. 2025 Nov 11;30(11) PMID: 41056445 PMCID: PMC12605803 SCOPUS ID: 2-s2.0-105021481152 10/07/2025

  • (McKay RR, Nazari SS, Elliott A, Ribeiro JR, Rose BS, Barata PC, Kilari D, Garje R, Agarwal N, Smith N, Antonarakis ES, Bagrodia A, Beltran H.) Oncologist. 2025 Nov 11;30(11) PMID: 41056440 PMCID: PMC12609168 SCOPUS ID: 2-s2.0-105021466827 10/07/2025

  • (Nizam A, Nguyen CB, Li J, Zabor EC, Msaouel P, Jiang CY, Alhalabi O, Oh E, Davidsohn MP, Epstein IB, Bakaloudi DR, Talukder R, Jindal T, Taylor AK, Glover MJ, Khaki AR, Lemke E, Mabey H, Abuqayas B, Jang A, Brown JR, Evans ST, Pywell C, Basu A, Bilen MA, Barata PC, Zakharia Y, Milowsky MI, Kilari D, Hoimes CJ, Shah SA, Emamekhoo H, Davis NB, Gupta S, Grivas P, Bellmunt J, Campbell MT, Alva AS, Koshkin VS.) Cancer Med. 2025 Oct;14(19):e71284 PMID: 41031719 PMCID: PMC12486332 SCOPUS ID: 2-s2.0-105017750478 10/01/2025

  • (Jindal T, Jiang CY, Alhalabi O, Nguyen CB, Oh E, Tsung I, Bakaloudi DR, Talukder R, Davidsohn M, Freeman D, Epstein IY, Ding CC, Nizam A, Glover MJ, Khaki AR, Taylor AK, Lemke E, Jang A, Evans ST, Shin D, Pywell C, Basu A, Bilen MA, Zakharia Y, Barata P, Milowsky MI, Brown J, Kilari D, Emamekhoo H, Hoimes CJ, Shah S, Davis NB, Gupta S, Grivas P, Bellmunt J, Alva A, Campbell MT, Koshkin VS.) Eur Urol. 2025 Sep 14 PMID: 40954009 SCOPUS ID: 2-s2.0-105018024297 09/16/2025

  • (Bo AY, Cheng YC, George B, Kilari D, Thompson JR, Jorns JM.) Arch Pathol Lab Med. 2025 Aug 01;149(8):734-740 PMID: 39722594 SCOPUS ID: 2-s2.0-105012641278 12/26/2024

  • (Zhong J, Jang A, Abuqayas B, Basu A, Benjamin DJ, Bhatlapenumarthi V, Bilen MA, Buch D, Chang M, Chin E, Darabi S, Dhanikonda N, Ghatalia P, Grigg CM, Grier AL, Jindal T, Jung J, Kilari D, Kumar HLS, Lee S, Neelands B, Pandya C, Pawalek J, Staggers J, Yildirim A, Zakharia Y, Zarrabi KK, Zimmerman M, Sledge G, Spetzler D, Elliott A, McKay RR, Barata PC.) Oncologist. 2025 Jun 04;30(6) PMID: 40536267 PMCID: PMC12204391 SCOPUS ID: 2-s2.0-105009317413 06/19/2025

  • (Jindal T, Jiang C, Alhalabi O, Nizam A, Nguyen C, Talukder R, Bakaloudi D, Davidsohn M, Freeman D, Glover M, Khaki AR, Evans S, Lemke E, Bose R, Sim W, Pywell C, Basu A, Kilari D, Barata PC, Bilen MA, Zakharia Y, Milowsky MI, Shah SA, Bellmunt J, Grivas P, Emamekhoo H, Davis NB, Gupta S, Hoimes C, Campbell MT, Alva A, Koshkin VS.) Eur Urol Oncol. 2025 Apr;8(2):258-262 PMID: 39709257 SCOPUS ID: 2-s2.0-105001942130 12/22/2024

  • (Basu A, Sidhom F, Hwang C, Ferguson J, Peyton C, Bae S, Kilari D, Desai A, Rais-Bahrami S.) J Natl Compr Canc Netw. 2025 Mar 28;23(3.5) PMID: 40154405 SCOPUS ID: 2-s2.0-105002494258 03/29/2025

  • (Li Q, Huang CC, Huang S, Tian Y, Huang J, Bitaraf A, Dong X, Nevalainen MT, Patel M, Wong J, Zhang J, Manley BJ, Park JY, Kohli M, Gore EM, Kilari D, Wang L.) Commun Med (Lond). 2025 Mar 04;5(1):61 PMID: 40038525 PMCID: PMC11880319 SCOPUS ID: 2-s2.0-86000110322 03/05/2025

  • (Raychaudhuri R, Tuchayi AM, Low SK, Arafa AT, Graham LS, Gulati R, Pritchard CC, Montgomery RB, Haffner MC, Nelson PS, Yu EY, Hawley JE, Cheng HH, Mo G, Chen DL, Antonarakis ES, Kilari D, Hope TA, Iravani A, Schweizer MT.) Eur Urol Oncol. 2025 Feb 06 PMID: 39920014 PMCID: PMC12325686 02/08/2025

  • (Patel MS, Almubarak M, Matta J, Ortiz-Sanchez C, Encarnacion J, Ruiz-Deya G, Dutil J, Dhillon J, Yamoah K, Berglund A, Park H, Kilari D, Balagurunathan Y, Wang L, Park JY.) Front Oncol. 2025;15:1541878 PMID: 40265030 PMCID: PMC12011585 04/23/2025

  • (Pierro MJ, Gallan A, Kilari D.) Transl Cancer Res. 2024 Nov 30;13(11):6403-6412 PMID: 39697750 PMCID: PMC11651800 12/19/2024

Publications of from the

© 2025 黑料官网.  All rights reserved.  | Terms and Privacy | Web Accessibility Statement

Non-Discrimination, Anti-Harassment, and Legal Compliance Statement
The 黑料官网 (黑料官网) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, military status, or other legally protected classification. 黑料官网 maintains full compliance with all applicable federal, state, and local laws and regulations in pursuit of our missions. Consistent with federal guidance, we affirm our commitment to individual merit, fairness, and equal treatment in all aspects of academic and institutional decision-making.

黑料官网's policies, federal and state laws, and regulations prohibit unlawful discrimination and harassment. Employees, learners, students, applicants, or other members of the 黑料官网 community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic.